Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program to Treat SMA
Shots:
- The FDA decision to lift the partial clinical trial hold of the OAV-101 IT clinical program is based on data from a nonclinical toxicology study in NHP
- The company plans to start P-III STEER study to evaluate the efficacy & safety of OAV-101 IT vs sham controls in treatment naïve patients aged b/w 2-18yrs. with SMA Type 2. The study is based on the P-I/II STRONG study that demonstrated an increase in HFMSE scores and clinical response in patients aged b/w ≥2 & <5yrs. with SMA Type 2
- OAV-101 IT is currently under investigation as a monothx. for one time treatment option to treat older patients with SMA
Ref: Novartis | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com